Related Experiment Videos
Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group
K J Tack1, D C Henry, W M Gooch
1Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA. tackk@aa.wl.com
Antimicrobial Agents and Chemotherapy
|May 21, 1998
Summary
Cefdinir offers a safe and effective 5-day treatment for group A beta-hemolytic streptococci (GABHS) pharyngitis, showing comparable efficacy to penicillin V. Its convenient dosing may improve patient compliance for strep throat treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Pharyngitis caused by group A beta-hemolytic streptococci (GABHS) is a common bacterial infection.
- Penicillin V has been the standard treatment, but concerns about compliance and resistance exist.
Purpose of the Study:
- To evaluate the safety and efficacy of oral cefdinir compared to oral penicillin V for treating GABHS pharyngitis.
- To assess GABHS eradication rates and clinical cure rates in patients receiving cefdinir or penicillin V.
Main Methods:
- A multicenter, randomized, controlled, investigator-blind study enrolled patients aged 13+ with GABHS pharyngitis.
- Patients received either oral cefdinir (300 mg BID) for 5 days or oral penicillin V (250 mg QID) for 10 days.
- Microbiological and clinical assessments were performed at multiple follow-up visits.
Main Results:
- GABHS eradication rates were 88.5% for cefdinir and 82.2% for penicillin V (P=0.053).
- Clinical cure rates were 89.0% for cefdinir and 84.6% for penicillin V (P=0.80).
- Adverse reaction rates were similar: 18.3% for cefdinir and 15.0% for penicillin V.
Conclusions:
- Five-day cefdinir treatment is a safe and effective option for GABHS pharyngitis.
- Cefdinir's twice-daily dosing and shorter duration may enhance patient compliance.
- Cefdinir presents a viable alternative for treating streptococcal pharyngitis.